Regentis Biomaterials Ltd. (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
This move is important because it signals the company’s transition from development to commercial stage, targeting a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. alone, where no off-the-shelf treatment is available. The training program aims to overcome a key barrier to adoption: surgeon proficiency with a novel implant. By starting at Humanitas Research Hospital, a renowned institution, Regentis can establish credibility and generate real-world evidence from early adopters.
The implications of this announcement extend beyond Regentis. GelrinC’s cell-free, off-the-shelf hydrogel represents a potential paradigm shift in cartilage repair, as it regenerates tissue without requiring cell harvesting or scaffolding. If successful, it could reduce healthcare costs and improve patient outcomes compared to existing treatments like microfracture or autologous chondrocyte implantation. For investors, the initiation of training activities is a concrete milestone that de-risks the commercialization timeline.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue. The company’s lead product, GelrinC, is resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process.
For more information, see the full press release here. Latest news and updates on RGNT are available in the company’s newsroom here.
